Corient Private Wealth
TRIB

Corient Private Wealth’s Trinity Biotech TRIB Stock Holding History

Corient Private Wealth’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,407
Closed -$9.45K – 2368
2023
Q4 		$9.45K Buy
+4,407
New +$10.5K ﹤0.01% 2239

Other funds holding TRIB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.37B AUM 19.97% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.4B AUM 24.68% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Corient Private Wealth's TRIB Position: Q1 2024 in Review

Corient Private Wealth sold out of Trinity Biotech (TRIB) in Q1 2024, closing a stake of 4,407 shares — an estimated $9.45K sold.

Corient Private Wealth first reported a position in TRIB in Q4 2023 and held it in 1 quarter. The position peaked at $9.45K in Q4 2023. 19 funds tracked by Wall St. Rank hold TRIB as of Q1 2024.

  • Corient Private Wealth reported no remaining Trinity Biotech position as of Q1 2024 after selling out during the quarter.
  • Corient Private Wealth sold 4,407 Trinity Biotech shares in Q1 2024, an estimated $9.45K.
  • Corient Private Wealth first reported a position in Trinity Biotech in Q4 2023 and held it in 1 quarter.
  • Corient Private Wealth's Trinity Biotech position peaked at $9.45K in Q4 2023.
  • 19 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2024.

Based on Corient Private Wealth's 13F filing for Q1 2024, filed 9 May 2024.